T&L (340570) Fundamentals 2026 — P/E 10.6x, Revenue Analysis | SniperIQ
T&L (340570) is a KR-listed Healthcare company in Medical - Devices with a market capitalization of ₩408.9B, trading at ₩51000.00 on the KOE. This SniperIQ fundamentals page covers T&L's valuation (P/E 10.6x, P/B 2.0x), profitability (net margin 24.5%), revenue (₩164.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is T&L's market cap?
T&L (340570) has a market capitalization of approximately ₩408.9B, trading at ₩51000.00 on the KOE. Market cap moves with the live share price.
What is T&L's P/E ratio?
T&L's trailing twelve-month P/E ratio is 10.6x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is T&L?
T&L runs a net profit margin of 24.5%, a gross margin of 44.2%, and an operating margin of 28.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does T&L generate?
T&L reported revenue of ₩164.2B for fiscal year 2025, with net income of ₩38.1B and earnings per share (EPS) of 4725. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does T&L pay a dividend?
T&L offers a trailing dividend yield of about 2.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is T&L financially healthy?
T&L carries a debt-to-equity ratio of 0.00x and a current ratio of 4.42x, with a market beta of 0.37. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is T&L a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For T&L (340570) the key facts are: market cap ₩408.9B, P/E 10.6x, revenue ₩164.2B, 52-week range 43100-68000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track T&L's full fundamentals live
Get T&L's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.